← BioNTech

What podcasts say about BioNTech

Every statement, with the speaker, the exact quote and the moment it was said.

What experts have said about BioNTech

3 statements · 1 positive · 2 negative

  1. Tierney BaumNegativeNov 17, 2026· BioCentury This Week

    BioNTech and Roche’s neoantigen program has struggled to demonstrate clinical efficacy.

    “that has really struggled to show efficacy in the clinic, including as monotherapy plus Keytruda.”

    Listen at 12:54

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
  2. Tierney BaumNegativeNov 17, 2026· BioCentury This Week

    BioNTech and Roche’s Phase 3 trial failed its progression-free-survival endpoint.

    “that failed to meet its progression-free survival endpoint.”

    Listen at 13:15

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
  3. Jim CramerPositiveAug 26, 2026· Mad Money w/ Jim Cramer

    BioNTech is a good company or investment.

    “I think you got a good one.”

    Listen at 36:04

    Open the episode · Mad Money w/ Jim Cramer 8/26/26

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.